-	

1	IN THE DISTRICT COURT OF THE UNITED STATES FOR THE NORTHERN DISTRICT OF OHIO	
2	EASTE	ERN DIVISION
3	IN RE: ORTHO EVRA PRODUCT	'S I.TARTI.TTV I.TTTCATTON
4	IIV IW. ORTHO EVIVI ITODOCI	
5	MELISSA BOWER, MONISHA SHANNON,	# 09-oe-40064 # 09-oe-40043
6	MEGHAN BORYCZ,	# 10-oe-40001
7	Plaintiffs,	
8	vs.	June 14, 2010 1:05 p.m.
9	TOTATOONI C TOTATOONI TEID NI	-
10	JOHNSON & JOHNSON, ET AL.,  Defendants.	
11	Defendants.	
12		
13	BEFORE THE H	OTION HEARING PROCEEDINGS ONORABLE DAVID A. KATZ
14	UNITED STA	ATES DISTRICT JUDGE
15	APPEARANCES:	
16	For the Plaintiffs:	Christopher Hood, Esq. Heninger Garrison Davis, LLC
17		2224 1st Avenue North P.O. Box 11310
18		Birmingham, AL 35202
19	For the Defendants:	Julie A. Callsen, Esq. Irene Keyse-Walker, Esq.
20		Tucker Ellis & West 1150 Huntington Building
21		925 Euclid Avenue Cleveland, Ohio 44115
22	Official Court Reporter:	·
23	official court reporter.	7-189 U.S. Court House 801 West Superior Avenue
24		Cleveland, Ohio 44113 216/357-7087
25	Proceedings recorded by me produced by computer-aided	echanical stenography; transcript

1	THE COURT: Good afternoon, ladies and
2	gentlemen.
3	I presume each of you have would you go off
4	the record for a moment?
13:06:48 5	(Discussion had off the record).
6	THE COURT: All right. Let's go back on the
7	record.
8	As you know we're here in the case of Bower
9	versus Johnson & Johnson for oral argument on the
13:06:48 10	defendant's pardon me motion for summary judgment.
11	There has been a response, a reply, and a
12	surreply, as to all of which I have read.
13	Since this is J & J's motion, I would presume
14	J & J would go first and have the right to reserve some time
13:07:04 15	for a reply.
16	How long do you each request?
17	MS. KEYSE-WALKER: Your Honor, I think my
18	total, 15 minutes would be fine.
19	MR. HOOD: I agree, Your Honor.
13:07:17 20	THE COURT: Very good.
21	MS. KEYSE-WALKER: I would like to reserve
22	five minutes.
23	THE COURT: I'm sorry?
24	MS. KEYSE-WALKER: I would like to reserve
13:07:25 25	five minutes.

1 THE COURT: Okay. 2 MS. KEYSE-WALKER: Thank you, Your Honor. 3 My name's Irene Keyse-Walker. I am 4 representing Johnson & Johnson. And there are actually 13:07:33 5 three motions for summary judgment in this case, the Bower 6 case, the Shannon case and the Borycz case. 7 Because this is a motion for summary judgment, we really only have two questions: What are the material 8 undisputed facts and what is the governing law that applies 13:07:50 10 to them? 11 We believe it is certainly undisputed that all 12 of the events at question here took place in Michigan. The 13 plaintiff is a Michigan resident. She was prescribed Ortho 14 Evra in Michigan. She was -- purchased her Ortho Evra in 13:08:04 15 Michigan. She was treated in Michigan. There is no event 16 that did not take place in Michigan that is important to her 17 product liability claim in this case. 18 Those are the material facts because those 19 dictate that since this is a diversity jurisdiction case, 13:08:23 20 that the law of Michigan controls her claim. 21 The law of Michigan codified their product 22 liability cause of action in statutes Chapter 600 inter 23 alia, statute 2946, Section 5, which, under Michigan law, 24 states that a manufacturer, when the product is a drug in a 13:08:46 25 product liability claim, the manufacturer is not liable and

the drug is neither defective nor unreasonably dangerous so long as it has been approved by FDA and that approval remains in good standing.

It is a broad immunity with a very specific and narrow exception. The narrow exception is when there has been information withheld or fraudulently misrepresented to the FDA such that the FDA either would have withdrawn its approval — would not have approved the drug or would have withdrawn its approval had it known of this information.

In this case, we have moved for summary judgment on the grounds that there is no evidence and plaintiff has no evidence that the FDA has found that there was fraud that would either have prevented the approval of Ortho Evra or caused it to be withdrawn.

And that's important because the governing law in this case is the *Garcia* case out of the Sixth Circuit which interpreted the Michigan statute and very specifically held that when you interpret the exception for the immunity in the Michigan statute, you have two ways you can go. If you want to say that state law or State Court or state juries' findings of fraud on the FDA is an exception, that is preempted by the *Buckman* case out of the U.S. Supreme Court because states cannot police the FDA. The FDA polices the FDA.

But if you can say that the FDA, that the

13:09:22 10

13:09:02 5

13:09:40 15

13:10:01 20

13:10:22 25

federal part of that exception has itself found fraud, then 1 2 you can raise that as an exception to the immunity that's 3 granted as part of the statute. 4 So that's the governing law that we have in 13:10:42 5 the Garcia case, and the arguments that have been made 6 against summary judgment have no application. 7 The first argument is, well, we have three counts that cite to Minnesota Consumer Sales Practices Act 8 violations, but, Your Honor, there is no basis for the 13:11:00 10 application of Minnesota law, much less Minnesota statutes, 11 to this action. 12 Minnesota could not even regulate sales in 13 Michigan of drugs if they wanted to. And Michigan residents 14 have no standing to assert Minnesota Sales Practices claims, 13:11:16 15 especially when they're urging personal injury in their 16 case. 17 So none of those counts provide any basis for 18 denying summary judgment in this case. 19 THE COURT: Those are the fraud deceit counts 13:11:31 20 6, 7 and 8? 21 MS. KEYSE-WALKER: Yes, Your Honor. 22 Then the second argument that's raised is that 23 the case of Wyeth versus Levine somehow changes the 24 controlling law of the Sixth Circuit in Garcia. 13:11:49 25 Well, in Wyeth versus Levine, it was a United

States Supreme Court case that, of course, did deal with 1 2 preemption, but it did not deal with Buckman preemption. 3 Buckman preemption asks the question: Do you 4 require proof of fraud on the FDA to establish your claim? 13:12:06 5 If you do, it's preempted. 6 And there is no presumption of preemption when 7 it comes to cases like Buckman because the question is not whether states are regulating state law. The question in 8 that case is are states trying to regulate the FDA. And the 13:12:26 10 FDA is the one policing it. 11 All Levine said, Wyeth versus Levine said if 12 you have a state common law claim, a product liability claim 13 for drugs, and the FDA has established what labeling should 14 be for that drug, the FDA's establishment of labeling does 13:12:47 15 not preempt the State Court claim. 16 That's not what we have. We don't have a 17 common law claim. 18 We have a codified claim under Michigan 19 statutes. And the Michigan statute very specifically 13:13:00 20 defines product liability actions as any action, any action 21 in the law or equity that involves a drug or product 22 liability, any action in law or equity that is -- causes or 23 results from -- any action in law or equity where you have

personal injury caused or resulting from a product.

So we have a very broad definition, and

24

13:13:27 25

there's no question that the allegations of personal injury 1 2 from consuming a drug in this case fall under the definition 3 of product action. 4 So you have a statutory claim that's being asserted and it's governed by statute, not the common law. 13:13:42 5 6 Levine, thus, has no effect on Garcia. 7 The other argument made is essentially that the Second Circuit, which had also interpreted the Michigan 8 statute, the Desiano case, is right and the Sixth Circuit is 13:14:02 10 wrong. 11 Well, we have two reasons that that doesn't 12 apply. The first is that the Sixth Circuit, since Levine 13 issued, eight months after Levine issued, issued its 14 decision in the Fragomeli case where it again reiterated 13:14:20 15 that in the Sixth Circuit the binding governing law is that 16 set forth in the Garcia case. Desiano came to a different conclusion. 17 18 different circuits can interpret federal laws and federal 19 preemption concepts and Buckman differently. 13:14:37 20 This case is governed by Michigan law and 21 Sixth Circuit authority, and in this case Johnson & Johnson 22 is entitled to judgment as a matter of law. 23 THE COURT: Would you refresh my recollection? 24 Did the Buckman -- did the Buckman case happen 13:14:54 25 to arise out of the diet drug MDL? I don't recall what the

product was.
MS. KEYSE-WALKER: My recollection, it was a
medical device case in <i>Buckman</i> .
THE COURT: And
MS. KEYSE-WALKER: And
THE COURT: Yeah, and the medical device was
before the Supreme Court as well the year before Wyeth.
MS. KEYSE-WALKER: In <i>Lohr</i> , yes.
THE COURT: Right.
MS. KEYSE-WALKER: And that's where the
Supreme Court made the distinction saying that fraud on the
FDA claims or claims that require proof of fraud on the
FDA are preempted because they are not a traditional area of
regulation by the states.
That, instead, is trying the state is
trying to regulate the FDA.
THE COURT: I ask the question about the
product involved only because as I recall the diet drug, the
diet drug litigation, a part of the assertion was fraud on
the FDA which at least this Court held was preempted, as
you've just articulated.
MS. KEYSE-WALKER: You're absolutely right,
Your Honor.
The name of the case, one of the Medtronic
cases, the Sixth Circuit held before Buckman issued that

1	there's no implied cause of action under the FDA for a
2	violation of the FDCA, so actually the Sixth Circuit
3	predicted Buckman in a sense and just analogized it to
4	trying to bring an action for violations of the FDA.
13:16:45 5	And that's exactly what this case
6	THE COURT: Then they found there was no
7	private right of action under those circumstances.
8	MS. KEYSE-WALKER: That's it. That's it.
9	THE COURT: Thank you.
13:16:53 10	MS. KEYSE-WALKER: Thank you.
11	THE COURT: Mr. Hood.
12	MR. HOOD: Thank you, Your Honor.
13	My name's Chris Hood. I'm here representing
14	the plaintiffs in the three cases you're hearing.
13:17:12 15	Riegel, I believe, is the Supreme Court case
16	involving medical devices that preceded by a year the Levine
17	decision, the Wyeth versus Levine where the Supreme Court
18	upheld the express Congressional preemption language, the
19	language Congress chose to insert into the MDA Device Act
13:17:33 20	preempting state law causes of action, and that's Riegel.
21	Buckman involved bone screws which are also
22	medical devices, and the lower Courts in Buckman found them
23	preempted under the MDA due to the express text and also
24	because the claim in Buckman was entirely derivative of the
13:17:55 25	FDA's own regulatory requirements that there was in plain

1 language you don't get a cause of action in state law, that 2 you cannot derive a state law cause of action from a 3 regulation promulgated by the FDA. 4 In the case of Buckman, the FDA required the 13:18:15 5 bone screw maker to state the purpose to which the bone 6 screws were going to be used. 7 The consultant employed by the manufacturer told the FDA, on submission, that it would be used for 8 orthopedic -- nonspinal orthopedic surgeries when, in fact, 13:18:31 10 the design all along, the business design all along was to 11 use them for spinal surgeries. And they had been 12 unsuccessful in getting them approved for that, so they 13 changed their tune, restated their purpose fraudulently, but 14 the whole reason they stated a purpose at all was that the 13:18:53 15 FDA had required them to do so under their regulations. 16 So the Supreme Court in Buckman said you 17 cannot derive a State Court cause of action from a 18 misrepresentation in fulfilling an FDA regulation. 19 That's all Buckman is. 13:19:06 20 It's quite a bit distant from this case. 21 quite a bit distant from Levine. And I'm afraid the Garcia 22 Court in the Sixth Circuit Court took Buckman and extended 23 it in a way that it's now untenable in light of Levine

because Levine says you can't preempt state law causes of

action unless Congress has made its intent express in the

24

13:19:27 25

text of the statute.

13:20:59 25

13:20:39 20

13:20:26 15

13:19:49 5

13:20:06 10

Garcia invalidated the Michigan statute based on Buckman, and it's an elaboration of Buckman or an extension of Buckman, rather, that's not going to hold up under Levine.

The Sixth Circuit said that the plaintiff in Garcia alleged she wanted to take advantage of the exception but hadn't alleged a federal finding of fraud, so they invalidated her claims and the Michigan exception language as applied in her case under the supremacy clause. Garcia is a federal constitutional decision, it's not a Michigan state law decision, it's a preemption decision, it's a decision by a Federal Court invalidating a state law under the federal supremacy, federal constitution supremacy clause.

And then as a judicial revision of that same statute, it says in other cases a plaintiff could avail himself or herself of that exception if they allege a federal finding of fraud.

There's no language in the Michigan statute that says the FDA has to find that the manufacturer misrepresented the information submitted to get drug approval. So *Garcia* is almost a whole clause decision. It's not in the -- it doesn't utilize text in the Michigan statute.

And it invalidated, as applied to the Garcia 1 2 plaintiff, it invalidated her claims -- invalidated the 3 exception, I'm sorry, in her case, but then made a rule that 4 you could go, in future cases you could use the exception 13:21:14 5 but you could only do so if the FDA has rendered its own 6 finding of fraud. 7 That's not going to stand up, I don't think, whether it's this case or somebody is going to invalidate 8 9 Garcia. 13:21:26 10 This Court can do so because under Sixth 11 Circuit authority, if a subsequent U.S. Supreme Court 12 decision comes along implicating a Sixth Circuit decision, 13 in this case Garcia followed by Levine, you can follow Levine and not follow Garcia. That's the Sixth Circuit's 14 13:21:46 15 own rule. 16 They have a prior precedent or prior panel 17 rule like most Federal Circuits where a three-Judge panel 18 can't invalidate a prior panel decision, but the Sixth 19 Circuit also says naturally, as you would think you would 13:22:02 20 agree, if a Supreme Court decision comes along and changes 21 the terrain, changes the rule, reshapes precedent, then the 22 Court, a three-Judge panel of the Sixth Circuit doesn't have 23 to follow the prior precedent.

Solomon is the Sixth Circuit case that states

24

that, among others.

13:22:20 25

1	And I believe
2	THE COURT: So your your position is that
3	the District Court has the first opportunity to distinguish,
4	for instance, this case from the coverage of Garcia under
13:22:48 5	the thesis that Wyeth changed the scope of the inquiry?
6	MR. HOOD: Correct.
7	THE COURT: Thank you.
8	MR. HOOD: You know, I say Levine. I'm
9	talking about <i>Wyeth</i> .
13:23:03 10	THE COURT: Correct.
11	MR. HOOD: Okay.
12	THE COURT: I call it Wyeth. You call it
13	Levine. It's the same case.
14	MR. HOOD: There's so many Wyeth decisions in
13:23:13 15	the Eleventh Circuit where I practice, we have some very
16	substantial ones referred to as Wyeth.
17	Another main point I'd like to make is that
18	well, now it slips my mind.
19	THE COURT: Come back to it.
13:23:36 20	MR. HOOD: Yeah.
21	I think that's it. We don't have much risk on
22	the Minnesota counts. They didn't offer any argument on
23	their papers on the Minnesota counts. They say in their
24	pleading we don't have standing to invoke Minnesota
13:23:57 25	statutory prescriptions proscriptions. They may be right

1 about that. 2 I do know in their pleadings, their answers in 3 this case, which is what they need to cite to if they're 4 going to try to prevail as a matter of law, they don't 13:24:11 5 invoke the Michigan statute in their answers to the three 6 complaints at issue: Bower, Shannon and Borycz. It's not 7 there. What they do plead is an affirmative defense 8 of preemption, federal preemption. Garcia is a preemption 9 13:24:30 10 case and decision. 11 So let's make sure we understand what we're 12 talking about. They're not invoking the Michigan statute in 13 their pleading. Garcia wasn't a case decided on the 14 Michigan statute. It was decided under the federal 13:24:41 15 preemption doctrine. 16 So this is federal constitutional law, not 17 Michigan statutory law, that is primarily involved here. 18 THE COURT: Well, isn't preemption in and of 19 itself a constitutional issue of the priority of, in those 13:24:59 20 instances, of federal law over state law?

It derives its origins from the preemption clause or clauses of the constitution, am I correct?

MR. HOOD: Sure, it does. Supremacy clause, yes, Your Honor, absolutely.

21

22

23

24

13:25:20 25

But I think I want to make sure we understand,

we're not talking about a Michigan statute that says your 1 2 plaintiff can't go forward without a federal finding. 3 Michigan statute doesn't say anything about a 4 federal finding of fraud. It just says she can go forward 13:25:34 5 and benefit from the exception in the statute if she adduces 6 evidence in a State Court in Michigan that the manufacturer 7 didn't tell the truth. That's what that statute is about. It's not 8 about a decision in a Federal Court in Ohio. We're here 9 13:25:53 10 because of the MDL and the transfer and the diversity 11 jurisdiction that originated prior to the transfer. 12 The Michigan statute says the plaintiff can go 13 forward with her lawsuit and benefit from the exception if 14 she shows that they didn't disclose what they were supposed 13:26:10 15 to disclose. We allege that. They don't deny our 16 allegations because there's no record yet for them to do 17 that. There's been no -- discovery hadn't concluded yet. 18 So that's what this Michigan statute says. 19 Garcia, the Sixth Circuit says, "Oh, no. We're going to rewrite that statute going forward and say 13:26:24 20 21 that plaintiff can't go forward unless they allege the FDA 22 has found that the manufacturer defrauded the FDA." 23 That's a different statute. That's a made-up, 24 that's a judicial revision, a whole clause change really to

the Michigan statute. I want to make sure we understand

13:26:44 25

1 that.

2

3

4

7

8

And the point that I had forgotten and need to point out, in *Levine* the Supreme Court said parallel functions, state law and federal law, are fine, are compatible. In fact, the Congress envisioned that the FDA's resources are limited.

So to have a State Court and a jury in a State Court sit in deliberation of evidence that a manufacturer didn't provide -- was not truthful to the FDA, does not usurp the FDA's function.

It's not a *Buckman* case. *Buckman* was decided because the plaintiffs' lawyers in that case created a new cause of action that had hitherto never before existed and had not existed until the action about these bone screws.

That's almost a night and day difference between a plaintiff in Michigan who sues for failure to warn like we do, or negligence like we do, a breach of a common law duty and has to make a complaint in her lawsuit such that she survives the narrowing of the common law that the legislature did when it said "We will give immunity to these manufacturers, except when that plaintiff can show that the manufacturer was not truthful."

And that's all we're saying we can do here, and when we get discovery we can do that.

Now, if *Garcia* is still good law, then the

13:27:00 5

13:27:20 10

11

13

12

14

13:27:42 15

1617

18

19

13:28:04 20

21

2223

24

13:28:19 25

defendants are correct.

1

2

3

4

6

7

8

9

11

12

13

14

16

17

18

19

21

22

23

24

13:29:46 25

13:29:25 20

13:29:04 15

13:28:37 5

13:28:48 10

I'm saying *Garcia* does not survive scrutiny under *Levine* and, like I say, it will happen somewhere. If not here, then somewhere.

Thank you.

THE COURT: Thank you, Mr. Hood.

MS. KEYSE-WALKER: Really briefly, Your Honor, I think we have narrowed the issue down considerably.

One, we know that plaintiffs disagree with the Sixth Circuit decision in *Garcia*. And, two, we focused it on the exception is what they rely on to avoid summary judgment.

Garcia was written by Judge Kennedy, concurred in by Judges Cook and Sutton. Now, I know those three Judges know a heck of a lot more than I do on any of these federalism issues, and Garcia is well-reasoned. They understood Buckman. They looked at this exception under the Michigan statute and they said, okay, the Michigan statute says if there's proof that the defendant withheld or misrepresented information to the FDA such that the FDA would have denied approval or withdrawn approval had they known this information, then your case can go forward.

So all of the proof has to be representations made to the FDA and what FDA would have done or would not have done.

Now, pragmatically, how do you do that? 1 2 do you establish what FDA would have done or wouldn't have 3 done? There are two ways. One, you can have a state jury, 4 one here in this case here, in this case here, in this case, 13:30:02 5 come up and say, "Well, yeah, we think they withheld 6 information. The FDA wouldn't have done it." Or you can say the FDA decides whether or not information was withheld 7 that would have prevented approval or caused withdrawal. 8 9 And that's all that Buckman says and that 13:30:21 10 Garcia says interpreting Buckman. As a practical matter, a federal decision of 11 12 how a federal agency acting to carry out congressional 13 intent in a federal statute cannot be proved by state 14 jurors. That is a purely federal function. 13:30:39 15 And that is why Buckman says there's no 16 presumption, there's no presumption regarding state statutes 17 that seek to prove violations against a federal agency 18 because that's not a traditional task of State Courts and 19 states. 13:30:58 20 States don't go around regulating federal 21 agencies. 22 THE COURT: Pardon me for interrupting again. 23 It seems to me that what you are saying, 24 contrary to Mr. Hood who pleads for the right to present 13:31:17 25 evidence gleaned through discovery that it would have been

fraud on the FDA, with no known fraud so delineated, your 1 2 position is that such evidence has been in the possession of 3 the FDA for over a decade -- I'm just giving you my 4 experience -- since 2006 in this case, and that no finding 13:32:08 5 of fraud on the FDA has been made and, therefore, he cannot 6 prove that there was information which, if it had been 7 disclosed, would have created a decision by the FDA that it had been defrauded by J & J. 8 That's pretty wordy, but isn't that where you 13:32:27 10 are? 11 MS. KEYSE-WALKER: I think that's a fair 12 reading of Garcia, Your Honor. 13 And I would say it's not my argument as much 14 as it's the Sixth Circuit's argument and the position that 13:32:38 15 they have taken. 16 It's really more a matter of process and 17 separation of power than saying who gets to say what impact 18 that information has on FDA, that FDA has had for the last 19 ten years. 13:32:51 20 Do you go through a citizens' petition process 21 under federal law where you can challenge a drug approval 22 and go right to FDA and say "You should withdraw approval," 23 or do you go to State Courts and say "Under state law I 24 should be able to prove what FDA did"? 13:33:08 25 THE COURT: Well, that was the Dragone case,

1	and in that case we said that they did not have the right in
2	that case to prove fraud on the FDA. There were other
3	things involved.
4	It would seem from your position then that the
13:33:31 5	FDA is the agency which, if it investigated, had made the
6	decision that a fraud was committed on the FDA under their
7	standards.
8	Okay. I understand your position.
9	MS. KEYSE-WALKER: And really that's all I
13:33:56 10	have to say, Your Honor.
11	I mean, I understand that a three-Judge panel
12	in the Sixth Circuit cannot overrule a three-Judge panel
13	unless but we're not in the Sixth Circuit. Fragomeli
14	said <i>Garcia</i> is binding precedent, it was decided after <i>Wyeth</i>
13:34:12 15	versus Levine.
16	We believe this is pretty much an open and
17	shut case.
18	Thank you.
19	THE COURT: Thank you very much.
13:34:18 20	I want to get one thing final that I knew I
21	had some notes on and I just found.
22	It would appear that the defendants' position
23	with respect to the bar under Michigan law is irrespective
24	of Counts 6, 7 and 8 and the asserted by defendant
13:37:15 25	interaction with Minnesota statute, and that plaintiffs'

1 position is that those counts are segregated and separate 2 from application of Michigan law. 3 But the defendants' position is that because 4 of being a resident of Michigan, it is the Michigan law 13:37:44 5 which applies and the Minnesota law cannot apply. 6 MS. KEYSE-WALKER: (Nods affirmatively). 7 THE COURT: Which is the position as to which Mr. Hood takes exception. 8 9 Have I stated it correctly? MR. HOOD: If I may, Your Honor. 13:38:02 10 11 The papers are not extensive for either side, 12 and the defendants said that because we agree, and we do, 13 that we're a Michigan resident taking a drug from a Michigan 14 doctor, ingesting it in Michigan and being hurt in Michigan, 13:38:26 15 that Michigan law is the be-all, end-all, it's the four 16 corners, paints the four corners of the lawsuit; there's no 17 Minnesota statute. 18 Our response was, well, if you're going to 19 imply there's no other counts in the case, because they 13:38:43 20 didn't address the Minnesota statutes in their papers --21 THE COURT: No, they look at the totality. 22 MR. HOOD: Yeah. And they are excluding by 23 saying what is, therefore there isn't Minnesota injuries 24 here, remedy under Minnesota statute, and I said we need an 13:38:59 25 argument.

I've seen class actions where people plead in 1 2 consumer laws that are state statutes providing remedy for 3 consumer fraud and deceptions and things like that, and 4 there are some arguments. I'm just saying that our interest at this 13:39:11 5 6 point is contesting the status of Garcia and whether it's 7 dispositive because the heart of our claims are a failure to 8 warn. 9 THE COURT: I know. 13:39:27 10 MR. HOOD: We have a common law fraud, too, 11 Count 4. Our fraud is not solely invested in a Minnesota 12 statutory scheme. It's common law. 13 Thank you. 14 THE COURT: Okay. 13:39:39 15 MS. KEYSE-WALKER: And I would like to reply 16 very briefly, Your Honor, that our argument is it's not only 17 when Michigan law applies and you go to the Michigan 18 statute, you have to go to the Michigan statutory definition 19 of a product liability claim and it includes advertising, promotion, fraud, warranty. Everything is included within 13:39:52 20 21 once you say Michigan law applies. 22 THE COURT: All right. I'll take it -- the 23 case will be -- cases will be taken under advisement. 24 And I want to thank you, Mr. Hood, although 13:40:11 25 it's probably even warmer in Birmingham.

MR. HOOD: At 4:00 a.m. this morning it was 82 and 90% humidity. THE COURT: We'll take this under advisement and let you know hopefully relatively quick, if I survive 13:40:31 5 this recent back attack. Thank you. Okay. We're off the record. (Discussion had off the record). (Proceedings concluded).